These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33647405)

  • 21. Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation.
    Moon C; Watts AB; Lu X; Su Y; Williams RO
    Mol Pharm; 2019 May; 16(5):1799-1812. PubMed ID: 30925839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles.
    Liao Q; Lam ICH; Lin HHS; Wan LTL; Lo JCK; Tai W; Kwok PCL; Lam JKW
    Int J Pharm; 2020 Jun; 584():119444. PubMed ID: 32445908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
    Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
    Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation.
    Raj Adhikari B; Sinha S; Lyons N; Pletzer D; Lamont I; Gordon KC; Das SC
    Eur J Pharm Biopharm; 2022 Nov; 180():260-268. PubMed ID: 36241076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties.
    Liu C; Lin L; Huang Z; Wu Q; Jiang J; Lv L; Yu X; Quan G; Li G; Wu C
    AAPS PharmSciTech; 2019 Jan; 20(2):85. PubMed ID: 30673901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
    Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
    Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
    Saboti D; Maver U; Chan HK; Planinšek O
    J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
    Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
    Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J; Gill C; Young PM; Traini D
    Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
    Lin Y; Yoon Kyung Chang R; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Int J Pharm; 2020 Dec; 591():119952. PubMed ID: 33059012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
    Li M; Chang RYK; Lin Y; Morales S; Kutter E; Chan HK
    Int J Pharm; 2021 Mar; 596():120200. PubMed ID: 33486032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.
    Bass K; Farkas D; Longest W
    AAPS PharmSciTech; 2019 Nov; 20(8):329. PubMed ID: 31676991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
    Wang W; Zhou QT; Sun SP; Denman JA; Gengenbach TR; Barraud N; Rice SA; Li J; Yang M; Chan HK
    AAPS J; 2016 Mar; 18(2):372-84. PubMed ID: 26603890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment.
    Patil SM; Diorio AM; Kommarajula P; Kunda NK
    Int J Pharm; 2024 Mar; 653():123920. PubMed ID: 38387819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
    Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
    Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.